Showing 1-10 of 97 results for "".
SCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. John H. Joseph on Clinical Trials for Injectables
https://practicaldermatology.com/programs/practical-dermatology/scale-2024-listen-dr-joel-cohen-interviews-dr-john-h-joseph-clinical-trials-injectables/26414/John H. Joseph, MD, joins Joel Cohen, MD, to discuss his work on clinical trials for neuromodulators and filler products at Music City SCALE.PD Asks: What would your staff say is the one thing you do that most aggravates them?
https://practicaldermatology.com/topics/practice-management/pd-asks-what-would-your-staff-say-is-the-one-thing-you-do-that-most-aggravates-them/19695/John E. Harris, MD, PhD explains why his frequent travel might leave his staff feeling a bit annoyed at times!Active Vitiligo: What to Look For
https://practicaldermatology.com/series/updates-vitiligo/active-vitiligo-what-to-look-for/24156/John E. Harris, MD, founding director of the Autoimmune Therapeutics Institute at the University of Massachusetts Chan Medical School, talks with Practical Dermatology Chief Medical Editor Neal Bhatia, MD, about the clinical signs of active vitiligo.Vitiligo: Current and Future Developments
https://practicaldermatology.com/conferences/maui-derm-2020/vitiligo-current-and-future-developments/19722/John E. Harris, MD, PhD reviews treatment advances and emerging science in vitiligo. From new topical agents to intriguing studies on a potential role for biologics, there is very good reason to be optimistic about the future of vitiligo treatment.Emerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments iChanging Approaches to Diagnosis and Research: DermTech's Contributions
https://practicaldermatology.com/topics/skin-cancer-photoprotection/changing-approaches-to-diagnosis-and-research-dermtechs-contributions/20137/John Dobak, MD, President/CEO of DermTech discusses the addition of the company's melanoma test to the National Comprehensive Cancer Network guidelines. He talks about the future of clinical trials, especially the role of genomics for identifying trial participants and allowing more precise analysisWhy Assessing Vitiligo Activity is Critical for Limiting Spread
https://practicaldermatology.com/conferences/maui-derm-2024/why-assessing-vitiligo-activity-is-critical-for-limiting-spread/20248/Chief Medical Editor Neal Bhatia, MD talks with “Mr. Vitiligo Himself,” John E. Harris, MD, PhD about the importance of determining whether vitiligo patients are active or stable in order to “shut off” spreading as soon as possible.Meaningful Approaches to Vitiligo
https://practicaldermatology.com/topics/general-topics/meaningful-approaches-to-vitiligo/18599/As science continues to uncover more about vitiligo and its treatment, dermatologists have more options than ever. But there's still work to be done. In this edition of Ask an Expert, host Adam Friedman, MD talks to John E. Harris, MD, PhD, Director of the Vitiligo Clinic and Research Center at UnivStevens-Johnson Syndrome: A Case Report
https://practicaldermatology.com/youngmd-connect/resident-resource-center/stevens-johnson-syndrome-a-case-series/23902/Successful treatment of drug-induced Stevens-Johnson Syndrome using cyclosporine and etanercept.All About Innovations at DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/all-about-innovations-at-derm2021/19965/Whether you’re a new or experienced learner in the dermatology PA/NP space, Sandri Johnson, FNP-BC, says the DERM2021 NP/PA CME Conference has something to offer. Attendees will learn about the latest innovations in the field.
- Prev
- Next